Dr Reddys

Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%

The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).

Dr Reddy's Lab to approach regulator for Sputnik Light as booster dose

Dr Reddy's Laboratories is hoping to go to a regulator for its single-dose Sputnik Light jab as booster dose for approvals by June-end or early July, a senior official said

75% of Nifty50 stocks trade below 200-DMA; look weak on the charts

Tech Mahindra and Wipro have tumbled over 30 per cent, while Apollo Hospitals Enterprise and Dr. Reddy's Laboratories have plummeted 22 per cent so far in calendar year 2022 (CY22)

Dr. Reddy's plans 'business continuity' in Russia despite Western pullout

Indian pharmaceutical major Dr. Reddy's Laboratories Ltd said on Wednesday it was focused on employee safety and business continuity in and around Russia

Fag-end selling drags Sensex for 6th day, dips 69 pts; RIL slips 1%

Closing Bell: The frontline S&P BSE Sensex fell 69 points to settle at 57,232 levels while the Nifty50 shut shop at 17,063 down 29 points

Mankind Pharma acquires two derma and respiratory brands from Dr Reddy's

Mankind Pharma to take over manufacturing, marketing and distribution of both products in India; entire integration and transition of the brands likely to be completed by March

Sensex slides 773pts, Nifty ends below 17400 amid global pullback; IT bleed

All the sectoral indices settled in the negative territory today with technology and public sector banks being the worst hit. The IT and PSB indices dropped nearly 3% and 2%, respectively

Stocks to Watch: L&T, Vedanta, NTPC, MCX, Dr.Reddy's, CBI, AU SFB, Textiles

BPCL, DLF, Dwarikesh Sugar, Exide, GIC Housing, HDIL, HPCL, IOC, Jindal Saw, KEC Intl, KPIT Tech, Krsnaa Diagnostics, SCI, Sun Pharma, Suven Life, Tata Motors and UCO Bank in focus ahead of Q3 results

Pricing trend, launches, stability of growth boosters for Dr Reddy's

Near-term outlook and valuation are expected to support the stock price

Sensex falls 884 pts from day's high, ends 77 pts down; Nifty holds 17,100

For the week, the Sensex and the Nifty indices are down 3% each

Dr Reddy's may underperform over concerns about launch of complex products

For rerating, it needs sustained growth in India, recovery in US

Dr Reddy's launches drug in US to treat high blood pressure, heart failure

The tablet is the generic therapeutic equivalent of Diovan, approved by the US Food and Drug Administration

Dr. Reddy's inks pact with Singapore firm to sell Trastuzumab biosimilar

Prestige BioPharma Ltd announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialisation of Trastuzumab biosimilar

Osho Krishan expects bullish bias in Balrampur Chini, Dr.Reddy's, Whirlpool

According to the technical analyst from Anand Rathi, most technical indicators are in favour of the bullish bias for these three stocks

Mandaviya holds meeting with Dr Reddy's Chairman on Sputnik V supply

Dr Reddy's is in a pact with RDIF to sell 250 million vials of Sputnik V in India.

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

Dr Reddy's extends fall on disappointing Q1; stock down 14% in 2 days

The stock of the pharmaceutical company was trading at its lowest level since April 9, 2021

Five Indian drugmakers to jointly start trial of Merck & Co's Covid-19 drug

(Reuters) - Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in India.

Dr Reddy's Laboratories announces commercial launch of Covid-19 drug 2-DG

: Dr. Reddy's Laboratories Ltd on Monday announced the commercial launch of 2-deoxy-D-glucose (2-DG). According to a press release issued by the city-based drug maker, Dr. Reddy's will supply the drug to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of the country. 2-DG manufactured by Dr. Reddy's has a purity of 99.5 per cent and is being sold commercially under the brand name 2DG. The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidized rate offered to Government institutions, it said. 2-DG, a oral drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's. Dr. G Satheesh Reddy, Secretary, Department of Defence (R&D) and Chairman, DRDO

Nomura remains overweight on India; Infosys, RIL, ICICI Bank among top bets

Going ahead, Nomura said, markets will focus more on corporate earnings rather than the broad economic growth in India